APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma
A Phase I/Ib Study of APX005M in Combination With Nivolumab and Cabiralizumab in Patients With Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma Whose Disease Has Progressed on Anti-PD- 1/PD-L1 Therapy
Sponsor: Apexigen America, Inc.
A PHASE1 clinical study on Advanced Melanoma and Non-small Cell Lung Cancer, this trial is completed. The trial is conducted by Apexigen America, Inc. and has accumulated 14 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
14 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Aug 2024 — Sep 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting PHASE1
-
Sep 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE1
-
Jun 2023 — Sep 2023 [monthly]
Active Not Recruiting PHASE1
▶ Show 9 earlier versions
-
Mar 2023 — Jun 2023 [monthly]
Active Not Recruiting PHASE1
-
Sep 2022 — Mar 2023 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Mar 2022 — Sep 2022 [monthly]
Recruiting PHASE1
-
Jan 2021 — Mar 2022 [monthly]
Recruiting PHASE1
-
Oct 2019 — Jan 2021 [monthly]
Recruiting PHASE1
-
Aug 2019 — Oct 2019 [monthly]
Recruiting PHASE1
-
Jul 2018 — Aug 2019 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jun 2018 — Jul 2018 [monthly]
Not Yet Recruiting PHASE1
-
May 2018 — Jun 2018 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Apexigen America, Inc.
- Bristol-Myers Squibb
- National Cancer Institute (NCI)
- Yale University
For direct contact, visit the study record on ClinicalTrials.gov .